Online inquiry

IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12856MR)

This product GTTS-WQ12856MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TLR2 gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001318787.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7097
UniProt ID O60603
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12856MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13904MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-2176
GTTS-WQ5493MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ11013MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ15131MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SYNT-001
GTTS-WQ12687MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ14256MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG-7116
GTTS-WQ6175MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ6819MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW